Roche To Make Further In-Roads With Evrysdi In Newborn And Older SMA Patients

50% Of Older US Patients Untreated

 
• By Andrew McConaghie

Roche’s Evrysdi is set to expand its license into pre-symptomatic children this year but the company is also focused on how to get greater numbers of older patients to seek treatment.

Roche_Basel
Roche's Evrysdi is third to market in SMA, but is building up a competitive profile to challenge Spinraza and Zolgensma • Source: Alamy

More from Neurological

More from Therapy Areas